26th Feb 2007 07:04
Sinclair Pharma PLC26 February 2007 Sinclair Pharma plc appoints Zoe McDougall as Director of Communications 26 February 2007, Godalming, UK. Sinclair Pharma plc ("Sinclair"), theinternational specialty pharmaceutical company, has appointed Zoe McDougall asDirector of Communications. Zoe will be responsible for investor relations andcorporate communications for Sinclair, at a time when the company is reportingstrong growth and plans to move from AIM to the main market in London. She re-joins Sinclair after a career break, during which she performed medicalhumanitarian work in Sri Lanka, and consulted in Communications and CSR. Zoe was previously with Sinclair for four years, in a marketing andcommunications role, during which time the company listed on AIM. Since thattime, Sinclair has evolved from £2.5m turnover (FY04) and a product portfoliosold only by marketing partners, to an international company with £11.6mturnover (FY06) and its own sales and marketing operation in five territoriesand showing substantial growth during the current financial year. Michael Flynn, CEO of Sinclair Pharma commented: "We are delighted the Zoe has agreed to take on the role as Director ofCommunications at what is an important stage in the company's development. Herin-depth understanding of the business and her experience in communications inthe healthcare sector will be invaluable to our on-going relationships with ourinvestors and the wider financial community." Prior to joining Sinclair, Zoe worked in medical marketing communications withPorter Novelli, where her experience included crisis management, pre-launchpreparations and marketing communications for clients such as GlaxoSmithKline,Novartis, Bristol-Myers Squibb and Bio Products Laboratories. Prior to this Zoeworked in sales at SmithKline Beecham. - Ends- Notes to editors: Sinclair Pharma plc Sinclair Pharma plc is an international specialty pharmaceutical company. Ithas a growing sales and marketing operation that is already present in France,Italy, UK, Spain and Portugal, and a complementary marketing partner networkthat spans more than 65 countries. Sinclair has proven expertise in acquiring or developing commercially attractiveand undervalued products, registering these products and bringing them to marketwithin a short time frame. The company focuses on niche therapeutic areas andits current portfolio includes products for dermatological conditions and oralhealth. Further information: Sinclair Pharma plcDr Michael Flynn, CEO Tel: +44 (0) 1483 410 600Zoe McDougall, Director of Communications Tel: +44 (0) 7973 792 520 UKCapital MS&LMary Clark, Halina Kukula Tel: +44 (0) 20 7307 5340 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma